Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.

Announced the first patient dosed in the Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial ...

The clinical-stage biotechnology company said Tuesday that the study will enroll at least 60 participants who will receive either one EP-104GI dose, two doses or a placebo. After six months, eligible ...

Noah Quish, a little Limerick boy who has undergone 15 surgeries related to the scoliosis he was born with, has been ...

Eupraxia Pharmaceuticals Inc. shares T.EPRX are trading unchanged at $7.60.

Matador Technologies Inc. (“Matador” or the “Company”) (TSXV: MATA, OTCQB: MATAF, FSE: IU3), the Bitcoin Ecosystem Company, is pleased to announce the launch ...

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Young Noah has already been diagnosed with a heart condition, severe obstructive Laryngomalacia, scoliosis, malformation of ...

Eosinophilic gastrointestinal diseases are exponentially more prevalent among patients with atopic diseases compared with the ...

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

Allergy and Clinical Immunology Division is marking World Allergy Week 2025 by highlighting the range of specialised services ...